Lactuvit syrup polymer bottle 200 ml

Pharmacological properties

In the colon, lactulose is transformed into low-molecular organic acids under the influence of intestinal flora. Due to the osmotic effect, these acids cause a decrease in pH in the lumen of the colon and an increase in the volume of intestinal contents. This stimulates peristalsis of the colon and normalizes the consistency of feces. Constipation is eliminated and the physiological rhythm of bowel emptying is restored.

In hepatic encephalopathy or hepatic coma and precoma, the therapeutic effect of lactulose is associated with inhibition of the growth of proteolytic bacteria by increasing the number of acidophilic bacteria (e.g. lactobacilli), transformation of ammonia into an ionized form due to acidification of the intestinal contents, laxative effect due to low pH and osmotic effect, change in nitrogen metabolism in bacteria due to stimulation of ammonia utilization by bacteria for protein synthesis. In the context of the above, it should be noted that the neuropsychiatric manifestations of hepatic encephalopathy cannot be explained only by high ammonia levels. However, the described mechanism of reducing its level by lactulose may be similar for other nitro compounds.

Lactulose, as a prebiotic, enhances the growth of beneficial bacteria such as bifidobacteria and lactobacilli, while inhibiting the growth of potentially pathogenic bacteria such as clostridia and E. coli. This helps restore the normal balance of intestinal flora.

Lactulose is almost not absorbed after ingestion and enters the intestine unchanged. When using Lactuvit in a dose of 40-75 ml, lactulose is completely metabolized by bacterial flora. When used in high doses, part of the drug may be excreted unchanged.

Indication

Constipation: regulation of the physiological rhythm of the intestine. Conditions requiring relief of defecation (hemorrhoids, after operations on the large intestine and anorectal area). Portosystemic hepatic encephalopathy (PSE): treatment and prevention of hepatic coma and precoma.

Application

The dose should be selected based on the clinical effect. The daily dose can be taken once or divided into 2 doses during the day using a measuring device.

A single dose should be swallowed whole and not held in the mouth for a long time.

The dosage regimen should be selected depending on individual needs. If the daily dose is taken in 1 dose, it should be taken at the same time, for example, during breakfast.

Dosage for constipation or conditions requiring easier bowel movements

Dosage for hepatic coma and precoma

The initial dose is 30-45 ml 3-4 times a day.

The maintenance dose is selected in such a way as to achieve 2-3 bowel movements per day with soft stools.

Lactuvit can be administered to comatose patients via a gastric tube or enema.

Conditions requiring stool softening

Dosage - as in the treatment of constipation.

Contraindication

Galactosemia, intestinal obstruction, hypersensitivity to the active substance or other components of the drug.

Side effects

In the first days of treatment, flatulence may occur, which usually disappears after a few days. When taking the drug in doses exceeding the recommended ones, abdominal pain and diarrhea may occur. In this case, the dose should be reduced. When using high therapeutic doses for a long period (usually only in patients with liver failure and encephalopathy), electrolyte imbalance may develop due to diarrhea.

Gastrointestinal tract

Flatulence, abdominal pain, nausea and vomiting. Diarrhea - when used in very high doses.

From the laboratory parameters

Electrolyte imbalance due to diarrhea.

Special instructions

If the therapeutic effect is insufficient within several days of treatment, it is necessary to review the recommended dose and frequency of administration.

Lactuvit should be used with caution in patients with lactose intolerance. The doses of the drug usually used to treat constipation do not cause disorders in patients with diabetes. For the treatment of hepatic coma and precoma, doses are usually much higher, which should be borne in mind when using the drug in patients with diabetes.

Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, the Lapp syndrome or glucose-galactose malabsorption should not take this medicine.

application in